News & Updates

Adding pyrazinamide (PZA) to the initial tuberculosis (TB) treatment in older patients may lead to an increase in the incidence of adverse events (AEs), particularly allergic reactions, but not in-hospital mortality, length of hospital stay, or hepatotoxicity, reports a study, which used data from the Japanese Diagnosis Procedure Combination inpatient database.

Treatment with cytisine shows comparable efficacy to that of nortriptyline for smoking cessation at 1 year, according to a study. In addition, adverse events for both medications are few and well-tolerated.

Treatment with benralizumab (BRZ) results in sustained remission in patients with severe eosinophilic asthma (SEA), particularly those with comorbid chronic rhinosinusitis with nasal polyps (CRSwNP) and reversible airflow limitation, reports a study.

In a cohort study of over 18 million individuals with up to 2 years of follow-up, the incidences of most mental illnesses were markedly elevated following COVID-19 diagnosis compared with before or without COVID-19, particularly among the unvaccinated and before COVID-19 vaccines became available.

A substantial number of allergic rhinitis (AR) cases in Singapore, particularly those with more severe symptoms, remain undiagnosed or receive inadequate treatment. This contributes to a hidden but significant burden of AR in the population, as shown in a study.

The presence of chronic bronchitis symptoms in COPD with T2 inflammation drives a more pronounced and significant benefit from mepolizumab in terms of reducing CAT scores, as shown in a post hoc analysis pooling data from two phase III trials — METREX and METREO

The antiviral molnupiravir confers continued but modest benefits in terms of reducing COVID-19–related symptoms up to 6 months after the index infection in a vaccinated population, according to a secondary analysis of the PANORAMIC trial.